Recombinant Mouse Osteoprotegerin/TNFRSF11B Fc Chimera, CF | R&D Systems 459-MO-100 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Mouse Osteoprotegerin/TNFRSF11B Fc Chimera, CF

catalog :

459-MO-100

quantity :

100 ug

price :

432 USD

citations: 26

Reference
Liao M, Zhu X, Lu Y, Yi X, Hu Y, Zhao Y, et al. Multi-omics profiling of retinal pigment epithelium reveals enhancer-driven activation of RANK-NFATc1 signaling in traumatic proliferative vitreoretinopathy. Nat Commun. 2024;15:7324 pubmed publisher
Park S, Peters M, Aguayo C, Farris M, Hughes R, Moore J, et al. Secretory factors released from high dose radiation-activated osteoclasts increase the expression level of pain-associated neuropeptides in sensory neuronal cultures. Res Sq. 2024;: pubmed publisher
Zhu J, Ma Y, Wang J, Wang Y, Ali W, Zou H, et al. The Mechanism of Osteoprotegerin-Induced Osteoclast Pyroptosis In Vitro. Int J Mol Sci. 2023;24: pubmed publisher
Kim J, Yang Y, Xie J, Lee O, Kim J, Hong J, et al. Regulation of sclerostin by the SIRT1 stabilization pathway in osteocytes. Cell Death Differ. 2022;: pubmed publisher
AlQranei M, Senbanjo L, Aljohani H, Hamza T, Chellaiah M. Lipopolysaccharide- TLR-4 Axis regulates Osteoclastogenesis independent of RANKL/RANK signaling. BMC Immunol. 2021;22:23 pubmed publisher
Paolino M, Koglgruber R, Cronin S, Uribesalgo I, Rauscher E, Harreiter J, et al. RANK links thymic regulatory T cells to fetal loss and gestational diabetes in pregnancy. Nature. 2021;589:442-447 pubmed publisher
Tong X, Chen M, Song R, Zhao H, Bian J, Gu J, et al. Overexpression of c-Fos reverses osteoprotegerin-mediated suppression of osteoclastogenesis by increasing the Beclin1-induced autophagy. J Cell Mol Med. 2021;25:937-945 pubmed publisher
Adhyatmika A, Beljaars L, Putri K, Habibie H, Boorsma C, Reker Smit C, et al. Osteoprotegerin is More than a Possible Serum Marker in Liver Fibrosis: A Study into its Function in Human and Murine Liver. Pharmaceutics. 2020;12: pubmed publisher
Hasegawa T, Kikuta J, Sudo T, Matsuura Y, Matsui T, Simmons S, et al. Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1. Nat Immunol. 2019;20:1631-1643 pubmed publisher
Gao X, Zheng J, Tu S, Cai B, Zeng R, Xiang L. Role of osteoprotegerin in the regulation of dental epithelial‑mesenchymal signaling during tooth development. Mol Med Rep. 2019;20:3035-3042 pubmed publisher
Dufresne S, Boulanger Piette A, Bossé S, Argaw A, Hamoudi D, Marcadet L, et al. Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy. Acta Neuropathol Commun. 2018;6:31 pubmed publisher
Barrott J, Illum B, Jin H, Hedberg M, Wang Y, Grossmann A, et al. Paracrine osteoprotegerin and β-catenin stabilization support synovial sarcomagenesis in periosteal cells. J Clin Invest. 2018;128:207-218 pubmed publisher
Bernardi S, Toffoli B, Bossi F, Candido R, Stenner E, Carretta R, et al. Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients. BMC Nephrol. 2017;18:219 pubmed publisher
Ealba E, Jheon A, Hall J, Curantz C, Butcher K, Schneider R. Neural crest-mediated bone resorption is a determinant of species-specific jaw length. Dev Biol. 2015;408:151-63 pubmed publisher
Matsushita M, Ozaki Y, Hasegawa Y, Terada F, Tabata N, Shiheido H, et al. A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts. PLoS ONE. 2015;10:e0116135 pubmed publisher
Mukai T, Ishida S, Ishikawa R, Yoshitaka T, Kittaka M, Gallant R, et al. SH3BP2 cherubism mutation potentiates TNF-?-induced osteoclastogenesis via NFATc1 and TNF-?-mediated inflammatory bone loss. J Bone Miner Res. 2014;29:2618-35 pubmed publisher
Takeshita S, Fumoto T, Naoe Y, Ikeda K. Age-related marrow adipogenesis is linked to increased expression of RANKL. J Biol Chem. 2014;289:16699-710 pubmed publisher
Rementer C, Wu M, Buranaphatthana W, Yang H, Scatena M, Giachelli C. An inducible, ligand-independent receptor activator of NF-?B gene to control osteoclast differentiation from monocytic precursors. PLoS ONE. 2013;8:e84465 pubmed publisher
Charles J, Hsu L, Niemi E, Weiss A, Aliprantis A, Nakamura M. Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J Clin Invest. 2012;122:4592-605 pubmed publisher
Onal M, Xiong J, Chen X, Thostenson J, Almeida M, Manolagas S, et al. Receptor activator of nuclear factor ?B ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem. 2012;287:29851-60 pubmed publisher
Schrader J, Rennekamp W, Niebergall U, Schoppet M, Jahr H, Brendel M, et al. Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death. Diabetologia. 2007;50:1243-7 pubmed
Nakamichi Y, Udagawa N, Kobayashi Y, Nakamura M, Yamamoto Y, Yamashita T, et al. Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts. J Immunol. 2007;178:192-200 pubmed
Berry J, Ealba E, Pettway G, Datta N, Swanson E, Somerman M, et al. JunB as a downstream mediator of PTHrP actions in cementoblasts. J Bone Miner Res. 2006;21:246-57 pubmed
Gustafsson B, Thommesen L, Stunes A, Tommeras K, Westbroek I, Waldum H, et al. Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem. 2006;98:139-51 pubmed
Bengtsson A, Ryan E, Giordano D, Magaletti D, Clark E. 17beta-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. Blood. 2004;104:1404-10 pubmed
Cao J, Venton L, Sakata T, Halloran B. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J Bone Miner Res. 2003;18:270-7 pubmed

product information

master code :

459-MO

SKU :

459-MO-100

product name :

Recombinant Mouse Osteoprotegerin/TNFRSF11B Fc Chimera, CF

unit size :

100 ug

description :

The Recombinant Mouse Osteoprotegerin/TNFRSF11B Fc Chimera, CF from R&D Systems is derived from NS0. The Recombinant Mouse Osteoprotegerin/TNFRSF11B Fc Chimera, CF has been validated for the following applications: Bioactivity.

target :

Osteoprotegerin/TNFRSF11B

category :

Proteins and Enzymes

buffer :

Lyophilized from a 0.2 ╡m filtered solution in PBS.

conjugate :

Unconjugated

purity :

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie« Blue Staining.

species :

Mouse

observed molecular weight :

85-95 kDa, reducing conditions

theoretical molecular weight :

70.9 kDa (monomer)

gene symbol :

Tnfrsf11b

details of functionality :

Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L-929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is 3-15 ng/mL in the presence of 12 ng/mL of cross-linked Recombinant Human TRAIL/TNFSF10 (Catalog #s 375-TL and MAB050 ).

endotoxin note :

<0.10 EU per 1 ╡g of the protein by the LAL method.

accessionNumbers :

Q6PI12

applications :

Bioactivity

source long :

Mouse myeloma cell line, NS0-derived mouse Osteoprotegerin/TNFRSF11B protein Mouse OPG Glu22-Leu401 (Gln138Arg) Accession # Q6PI12 IEGRMD Human IgG1 (Pro100-Lys330) (Thr276Ala) 6-His tag N-terminus C-terminus

source short :

NS0

USD :

432 USD

alt names :

OCIF, OCIFMGC29565, OPG, OPGtumor necrosis factor receptor superfamily member 11B, Osteoclastogenesis inhibitory factor, Osteoprotegerin, TNFRSF11B, TR1, tumor necrosis factor receptor superfamily, member 11b

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, -20 to -70 ░C under sterile conditions after reconstitution.